Carterra’s new Vega surface plasmon resonance (SPR) platform, described in an industry interview with chief commercial officer Tim Germann, boosts throughput to tens of thousands of interactions per day and brings real‑time, label‑free binding data into primary screening workflows. Vega lets teams assess kinetics, affinity and off‑target binding far earlier in discovery, potentially reducing false leads and accelerating triage for antibodies and small molecules. Companies adopting high‑throughput SPR could shorten lead selection cycles and refine candidate portfolios before expensive downstream work.